Market Overview

Delcath Announces CHEMOSAT Treatment Milestones In Europe, Over 250 Treatments Have Been Completed By Physicians


Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have completed over 250 treatments with Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) since the second generation of CHEMOSAT was launched. Physicians in Europe have used CHEMOSAT in both commercial and clinical settings to treat patients for a wide variety of cancers in the liver, including ocular melanoma liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and liver metastases from colorectal cancer, breast cancer and others.

Concurrently, Delcath announces the activation of the prestigious Harley Street Clinic (HSC) in London, United Kingdom as a CHEMOSAT treatment site. HSC is a specialist private hospital that provides complex cardiac, cancer and neurosciences care. HSC is supported by HCA International and owned by HCA Inc., the largest provider of private healthcare in the world. Julian Hague, M.D., an interventional radiologist with HSC, performed the clinic's first CHEMOSAT treatment on a patient with breast cancer liver metastases in November.

"I believe the future of interventional oncology lies in tailoring the treatment to the individual patient," said Dr. Hague. "I believe having CHEMOSAT in our treatment armamentarium represents major progress in our ability to provide liver directed therapies to patients."

"The completion of our 250th CHEMOSAT treatment and the activation of the Harley Street Clinic highlight the steady progress our team has made in expanding the clinical adoption of this therapy," said Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath Systems. "Over the past two years our team has built a strong commercial and clinical footprint for CHEMOSAT in Europe. We look forward to continuing to build on this momentum in the New Year in order to increase revenue and, importantly, to enhance the lives of patients suffering with these life-limiting conditions."


Related Articles (DCTH)

View Comments and Join the Discussion!

Posted-In: News FDA Press Releases